01 — What is it?
Semax is an ACTH-fragment analogue studied particularly in Russia for neurologic and cognitive indications. Human clinical studies include ischemic-stroke rehabilitation research.
Database / Research Profiles / Semax
RESEARCH PROFILE
SEMAX
ACTH(4-10)-derived heptapeptide
Neuro / cognitionLimited human clinical evidence
EVIDENCE SNAPSHOTLIMITED HUMAN CLINICAL EVIDENCE
Some human trials report changes in BDNF and neurologic outcomes, but the evidence base is not equivalent to large modern international Phase 3 programs.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Neuro / cognition. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: YESPersonal dosing protocol: NOT PROVIDED
Some human trials report changes in BDNF and neurologic outcomes, but the evidence base is not equivalent to large modern international Phase 3 programs.
04 — Mechanism / biology
Semax is an ACTH-fragment analogue studied particularly in Russia for neurologic and cognitive indications. Human clinical studies include ischemic-stroke rehabilitation research.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.